Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026

Spyre Therapeutics (NASDAQ:SYRE) is one of the 17 biotechnology stocks with more than 50% upside.

As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish. The stock had received coverage from 7 analysts, all of whom assigned Buy ratings. It has a projected median 1-year price target of $57.86, offering an upside of more than 66%.

On January 22, Spyre Therapeutics (NASDAQ:SYRE) announced plans for 2026, where it will prioritize six POC readouts. The company mentioned that its SKYLINE ulcerative colitis trial has seen SPY001 enrollment complete ahead of schedule, accelerating Part A readouts to sometime in the second quarter. The SKYWAY basket trial on rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis remains on track for fourth-quarter readouts in 2026. Financially, $783 million in pro forma cash, cash equivalents, and marketable securities as of September 30, 2025, provides a runway through the second half of 2028. The company also appointed Kate Tansey Chevlen as Chief Commercial Officer, who is a seasoned biopharma commercial leader.

Spyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company developing advanced antibody therapeutics for patients with inflammatory bowel disease (IBD). The company focuses on next-gen cures for conditions such as ulcerative colitis and Crohn’s disease. Its current pipeline includes SPY001, SPY002, SPY003, and some combination therapies.

While we acknowledge the risk and potential of TSLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TSLA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.